The global CNS Therapeutic
Market is expected to reach USD 128.9 billion by
2025, according to a new report by Grand View Research, Inc. Rising prevalence
of mental illnesses and increasing awareness regarding psychiatric disorders
are driving market growth. In addition, expanding geriatric population and
rising prevalence of lifestyle-associated CNS disorders are increasing global
demand for CNS therapeutics.
Mental health segment accounted for the largest
market share in 2016. It is expected to retain its dominance over the forecast
period owing to developing therapeutic options for mental diseases such as
personality disorders and binge eating disorders. This segment is followed by
degenerative disorders segment. There is growing awareness regarding neurodegenerative
diseases owing to increase in initiatives by government and nongovernment
organizations, such as Alzheimer’s and Related Disorders Society of India.
These organizations conduct awareness campaigns and conferences, such as Asia
Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia,
which encourage the adoption of treatment for degenerative and mental
disorders.
Cancer segment is expected to emerge as the fastest
growing segment in the Central Nervous System therapeutics market. High demand
for effective treatment and a large number of drugs in later phases of clinical
trials are factors expected to propel the growth of the segment.
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/central-nervous-system-cns-therapeutic-market
Further Key Findings from the Report Suggest:
- Global mental health therapeutics revenue
accounted for 48% share in 2016 and is expected to grow at a significant
rate from 2016 to 2025
- Global demand for the treatment of
Parkinson’s and Alzheimer’s diseases is anticipated to witness extensive
growth over the next 9 years
- The industry in Asia Pacific is expected
to report fastest growth over the forecast period owing to various
developments across major economies of the region, especially in the
mental health sector.
- Key players including Pfizer, Inc.; Teva
Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson & Johnson
Services, Inc.; Eli Lilly and Company; and Novartis AG led the global CNS
disease treatment market by capturing a majority share
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment